April 29, 2024
A New Jersey federal judge on Monday shot down a pair of challenges to the Medicare drug price negotiations, extending a string of court victories for the Biden administration as it defends the talks as entirely voluntary.
March 07, 2024
A New Jersey federal judge on Thursday bristled at the position by pharmaceutical companies that Medicare's drug price negotiation program is an unconstitutional "taking" that undercuts their bottom line, suggesting that the drug powerhouses needed more numbers to back their argument.
January 11, 2024
A group of economists and health policy scholars urged a New Jersey federal court Thursday to reject Janssen Pharmaceuticals Inc.'s bid for a win without trial in its challenge to Medicare drug price negotiations, arguing the program makes the drug market more, not less, competitive.
October 23, 2023
The AARP, American College of Physicians and other groups urged a New Jersey federal court Monday to reject challenges from Bristol-Myers Squibb Co. and Janssen Pharmaceuticals Inc. to the Medicare drug price negotiation program, arguing that preserving the negotiations is vital for public health.
October 17, 2023
The U.S. Department of Health and Human Services urged a New Jersey federal judge Monday not to grant an early win to drugmakers challenging a federal drug-price program, arguing the companies have "nothing more" than a dispute with policy and don't have to participate in Medicare.
October 06, 2023
Lawsuits from Big Pharma and big business challenging Medicare's new power to negotiate drug prices are hurtling toward pivotal tests of lofty legal theories and the Biden administration's creative efforts to save its signature health care accomplishment. Here, Law360 explores the litigation landscape in a detailed map that will be updated as the saga evolves.
September 01, 2023
Novartis Pharmaceuticals Corp. on Friday joined the growing list of pharmaceutical companies challenging the Inflation Reduction Act, filing suit in New Jersey federal court just days after the Biden administration revealed the list of drugs in the inaugural round of Medicare price negotiations.
August 14, 2023
A barrage of legal challenges to landmark legislation empowering Medicare to negotiate drug prices is little more than a failed lobbying campaign "masquerading as constitutional theory," the U.S. Department of Health and Human Services said in its first official rebuttal in the high-stakes litigation.
July 21, 2023
A head-spinning spree of rulings and new lawsuits in 2023's first half is reverberating across the health care industry and auguring a dizzying denouement in the year's final months that may well upend assumptions about drug prices and approvals, the False Claims Act and the powers of federal regulators.
July 18, 2023
Johnson & Johnson unit Janssen Pharmaceuticals has launched a suit to challenge a system allowing Medicare to negotiate prescription drug prices under a federal inflation deterrent, marking at least the sixth lawsuit to fight the provision.